A retrospective, single-institution, real-world study for efficacy and safety of Pembrolizumab in patients with heavily treated recurrent gynecologic malignancies
Latest Information Update: 04 Nov 2020
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Gynaecological cancer; Leiomyosarcoma; Neuroendocrine carcinoma; Ovarian cancer; Sarcoma; Squamous cell cancer; Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Nov 2020 New trial record
- 01 Oct 2020 Results published in the Yonsei Medical Journal